RxDoctor Payments Data

Ramla Sharif, MD

Geriatric Medicine · Kennesaw, GANPI 1346561677

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 47.0% of the total. Reporting peaked in 2024 at $285 and has fallen 83.5% since, to $47 in 2025.

$518in general payments, 2019–2025

Across 25 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$244
  • Lilly USA, LLC$59
  • Novo Nordisk$47
  • Novartis$30
  • Currax Pharmaceuticals LLC$25
  • AbbVie$19
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$49395%
  • Education$255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$518 in reported general payments places this provider in the 65th percentile of 75 geriatric medicine providers in Georgia.

See all geriatric medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$71,870
Medicare patients
170
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$28,510
JanumetSitagliptin Phos/Metformin Hcl21$23,481
EliquisApixaban24$14,552
Breo ElliptaFluticasone/Vilanterol19$13,908
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,969
Memantine Hcl68$2,284
Levothyroxine Sodium186$2,138
Donepezil Hcl79$1,491
Atorvastatin Calcium205$1,464
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$1,394
Metoprolol Succinate89$1,339
Albuterol Sulfate HfaAlbuterol Sulfate34$1,181
Omeprazole80$1,146
Memantine Hcl ErMemantine Hcl16$1,116
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$1,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$47$28,51018 claims
AstraZenecaBreztri Aerosphere$244$11,96913 claims
Almatica Pharma LLCSertraline Hcl$17$53780 claims
Lilly USA, LLCOlanzapine$59$40823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 75 geriatric medicine providers in Georgia.

Other geriatric medicine in Kennesaw

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →